Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2

Kageyama, Takahiro; Tanaka, Shigeru; Etori, Keishi; Hattori, Koto; Miyachi, K; Kasuya, Tadamichi; Iwamoto, Taro; Ikeda, Kei; Igari, Hidetoshi; Yokote, Koutaro; Nakajima, Hiroshi

doi:10.1016/j.vaccine.2022.02.045

Cited by 3 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The precise mechanisms for higher reactogenicity after the second or subsequent doses of Covid-19 mRNA vaccine are still unclear, but several studies have shown that systemic adverse reactions after the second dose are associated with higher levels of anti-spike IgG protein in the serum post-vaccination (41)(42)(43)(44). This higher levels of anti-spike IgG protein has been reported to correlate with increased naïve and transitional B cells and activated CD8+ T cells (45). Although the serological data for these patients is unavailable, it is likely that the first dose served to prime the immune system and the cumulative effects resulted in a shift in the B cell and CD8+ T cell population that may have triggered the autoimmune flare or reactivation of the latent infections (46).…”

Section: Discussionmentioning

confidence: 99%

Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center

Chew

Wiryasaputra

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundWe report vaccine and booster-related uveitis in Singapore, a country with high vaccination and booster rates to highlight the differences and potential role of prophylactic treatment for sight-threatening infectious uveitis.MethodsClinical data extracted from the de-identified uveitis database in Singapore National Eye Center. Six patients (eight eyes) developed uveitis within 14 days after undergoing COVID-19 vaccination (primary and/or booster).ResultsAll patients received two doses of COVID-19 vaccination, and 1.39% (6/431) developed COVID-19 vaccine-related uveitis. Fifty-percent% (3/6) with non-infectious anterior uveitis (NIAU) presented with a non-granulomatous anterior uveitis (AU). The remaining (3/6) presenting with a granulomatous AU were diagnosed with reactivation of cytomegalovirus, varicella-zoster virus and toxoplasma chorioretinitis, respectively. All the patients responded to definitive treatment specific to their diagnosis. The mean visual acuity at presentation was 0.36 ± 0.20 logMAR and improved to 0.75 ± 0.09 (p = 0.009). Mean time from vaccination to uveitis was 9.7 (range: 3–14) days. All patients developed uveitis after second vaccination dose. 16.67% (1/6) patients had a recurrence after the third booster dose. None of the three patients with infectious uveitis developed recurrence but had received maintenance therapy up to or during the booster.ConclusionUveitis after COVID-19 vaccination is uncommon. In our series, a higher rate of reactivations of latent infections was seen. With definitive treatment, all cases were self-limited without systemic sequelae. Prophylactic treatment during booster vaccine may prevent reactivation of sight-threatening infections and reduce morbidity although risk-benefits should be considered for individual patients given the low rate of occurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center

Chew

Wiryasaputra

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…However, middle-aged women receiving HRT did not respond to the second vaccination. The reason remains clear, but some B cell activation might be concerned [18].…”

Section: Discussionmentioning

confidence: 99%

Impact of Menopausal Hormonal Therapy on Anti-SARS-Cov-2 Antibody Titers in Middle-Aged Women

Miyachi,

Yamamoto,

Sasse

et al. 2024

CLINICMED

View full text Add to dashboard Cite

Aim: Postmenopausal women often contract the common cold. Following treatment with HRT, symptoms resolve in some women. We hypothesize menopausal hormone therapy (MHT) may increase anti-SARS-Cov-2 IgG antibody titers, leading to greater resilience against COVID-19 infection. Methods: 219 patients were enrolled. Anti-SARS-Cov-2 IgG antibody titers were measured, and the number of days since the second SARS-Cov-2 vaccination was recorded. Linear regression analysis was performed to examine the relationship between these two variables for patients receiving MHT, patients with rheumatoid arthritis (RA) receiving methotrexate and non-MHT/non-RA (NMR). Analysis was further divided into groups aged <50, age 50 to 60, and age >60. Results: Anti-SARS-Cov-2 IgG antibody titers in the MHT group were significantly higher than NMR aged >50 (p < 0.05). In addition, anti-IgG antibody values in NMR were significantly higher than in patients with RA aged >60 (p < 0.05). Conclusion: MHT results in increased production of anti-SARS-Cov-2 IgG antibodies in women aged >50. This may confer additional protection against SARS-Cov-2 infection. Women with RA on methotrexate over 60 have lower antibody titers than NMR aged >60.

show abstract

Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities

Suita,

Ohfuji,

Kasamatsu

et al. 2023

Vaccine: X

View full text Add to dashboard Cite

Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2

Cited by 3 publications

References 16 publications

Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center

Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center

Impact of Menopausal Hormonal Therapy on Anti-SARS-Cov-2 Antibody Titers in Middle-Aged Women

Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities

Contact Info

Product

Resources

About